Inmune Bio INMB
NASDAQ INMB
$1.10 +0.00 (+0.00%)
At close: Nov 11, 2026 · 4:00 PM EST

Inmune Bio (INMB) Notes Payables (2022 - 2025)

Updated

Analysis

Inmune Bio (INMB) Notes Payables (2022 - 2025) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Inmune Bio 30.71 Mn -50.14 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 623,000.00
Mar 31, 2025 146,000.00
Dec 31, 2024 140,000.00
Sep 30, 2024 135,000.00
Jun 30, 2024 130,000.00
Mar 31, 2024 125,000.00
Dec 31, 2023 119,000.00
Dec 31, 2022 87,000.00
API Access

Inmune Bio Notes Payables API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=notes-payables&ticker=INMB&period=max&api_key=YOUR_API_KEY